V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330012883 | 330012014 | 0 | 76.4 | Curative (C) | null | 2015-10-18 | CYCLOPHOSPHAMIDE + VINORELBINE | N | N | 330025032 | BENDAMUSTINE |
| 330012884 | 330009256 | 1.73 | 88 | Palliative (P) | 2018-04-01 | 2018-04-01 | UKALL14- Cons Cycle 1 | N | null | 330025041 | BEVACIZUMAB + IRINOTECAN |
| 330012885 | 330005980 | null | 59.8 | Curative (C) | 2019-07-10 | 2019-08-21 | STS Rhabdomyosarcoma RMS 2005 IVA | N | null | 330025052 | LIPOSOMAL CYTARABINE |
| 330012886 | 330005986 | 1.79 | 67.5 | Palliative (P) | 2017-04-18 | 2017-08-30 | Bortezomib +/- Dexamethasone | N | N | 330000507 | TRASTUZUMAB |
| 330012887 | 330006008 | null | 72.1 | Curative (C) | 2015-06-26 | 2015-06-26 | AML 18 TRIAL | 2 | null | 330004663 | PEI |
| 330012888 | 330006013 | 0 | 57.1 | Palliative (P) | 2017-03-17 | 2018-01-21 | AML17 TRIAL | 02 | N | 330004965 | CYCLOPHOSPHAMIDE + DOXORUBICIN |
| 330012889 | 330006023 | 1.59 | 70 | Palliative (P) | 2016-03-12 | 2016-03-14 | Fludarabine + Melphalan RIC Allo | Y | N | 330006361 | DOXORUBICIN + HD MTX |
| 330012890 | 330006034 | 1.62 | null | Disease modification (D) | 2018-06-08 | 2018-06-08 | CTD | 02 | N | 330007632 | IMATINIB |
| 330012891 | 330006061 | null | 86.6 | Palliative (P) | 2017-08-23 | 2017-08-27 | Cytarabine HD + Rituximab | N | null | 330010514 | DE-ESCALATE TRIAL |
| 330012892 | 330009303 | 1.79 | null | Palliative (P) | 2019-04-13 | 2019-04-13 | DACTINOMYCIN + CYCLO + VINCRISTINE | N | null | 330011080 | DHAP |
| 330012893 | 330006079 | null | 119 | Adjuvant (A) | 2015-12-05 | 2015-12-05 | Triple Intrathecal | 02 | N | 330012831 | IVA |
| 330012894 | 330006101 | null | 95.2 | Palliative (P) | null | 2015-03-03 | Doxorubicin + Methotrexate | null | null | 330016564 | MAP + MIFAMURTIDE |
| 330012895 | 330012041 | 0 | null | Palliative (P) | 2018-06-24 | 2018-06-24 | CAP | 02 | N | 330020339 | CLOFARABINE + CYCLO + CYTARABINE + ETOP |
| 330012896 | 330006122 | 0 | 78.3 | Palliative (P) | null | 2017-11-28 | Hydroxycarbamide | N | N | 330020858 | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE |
| 330012897 | 330011093 | 1.7 | 62.2 | Palliative (P) | 2018-03-09 | 2018-10-18 | Triple Intrathecal | N | N | 330021332 | IFOSFAMIDE |
| 330012898 | 330006144 | 1.79 | 35.8 | Palliative (P) | 2017-05-09 | 2017-06-06 | STS Rhabdomyosarcoma RMS 2005 VA | N | N | 330024623 | CISPLATIN + GEMCITABINE |
| 330012899 | 330006154 | 1.58 | 77.2 | Palliative (P) | 2017-08-16 | 2017-09-01 | AML17 TRIAL | N | N | 330007206 | VINCRISTINE |
| 330012900 | 330009353 | null | null | Disease modification (D) | 2019-03-24 | 2019-03-24 | DACTINOMYCIN + CYCLO + VINCRISTINE | N | null | 330009579 | MITOTANE |
| 330012901 | 330011538 | 1.6 | 15.3 | Palliative (P) | 2016-07-18 | 2016-07-30 | NB HRNBL-1 COJEC Ind COURSE B | 02 | null | 330000004 | NOT MATCHED |
| 330012902 | 330002938 | 0 | null | Neo-adjuvant (N) | null | 2014-06-10 | EW Rel rEECur Gemcitabine/Docetaxel | Y | N | 330000050 | NOT MATCHED |
| 330012904 | 330002952 | 0 | 43.8 | Adjuvant (A) | 2018-05-20 | 2018-12-03 | CNS LGG 2004 03 cons vinc +cyclo | Y | null | 330000081 | NOT MATCHED |
| 330012905 | 330002961 | 1.08 | 49 | Adjuvant (A) | 2019-01-17 | 2019-01-18 | NB HRNBL-1 ch14.18/CHO only (trial) | N | null | 330000144 | NOT MATCHED |
| 330012906 | 330002972 | null | 125.7 | Curative (C) | 2017-02-14 | 2017-05-14 | NB HRNBL-1 ch14.18/CHO only (trial) | N | N | 330000172 | NOT MATCHED |
| 330012907 | 330002985 | null | 12.5 | Curative (C) | 2013-05-23 | 2015-01-27 | NB HRNBL-1 COJEC Ind COURSE C | null | null | 330000242 | NOT MATCHED |
| 330012908 | 330002989 | 0 | 28.2 | Curative (C) | 2017-02-04 | 2017-09-30 | NB HRNBL-1 COJEC Ind COURSE C | Y | N | 330000247 | NOT MATCHED |
| 330012909 | 330007600 | 0 | 13.1 | Curative (C) | 2018-02-27 | 2018-03-05 | NB Rel CCLG guidelines Cyclo-Topotecan | null | null | 330000263 | NOT MATCHED |
| 330012910 | 330003000 | 1.66 | 107 | Curative (C) | 2017-06-16 | 2018-03-13 | CISPLATIN + RT | N | null | 330000299 | CISPLATIN + RT |
| 330012911 | 330003004 | 0 | 89.8 | Adjuvant (A) | 2015-02-25 | 2015-02-26 | null | 02 | Y | 330000305 | NOT MATCHED |
| 330012912 | 330003011 | null | 42.3 | Palliative (P) | 2016-08-07 | 2016-08-18 | NB HRNBL-1 COJEC Ind COURSE C | N | null | 330000353 | NOT MATCHED |
| 330012913 | 330003015 | 1.68 | 97.3 | Not known (9) | 2017-12-14 | 2018-02-09 | Cisplatin + Radiotherapy | N | Y | 330000390 | CISPLATIN + RT |
| 330012914 | 330007616 | 1.76 | null | Curative (C) | null | 2015-06-17 | CISPLATIN + RT | 02 | Y | 330000410 | CISPLATIN + RT |
| 330012915 | 330003046 | null | 37.2 | Adjuvant (A) | 2013-05-11 | 2013-08-12 | NB HRNBL-1 Isotretinoin | N | N | 330000516 | NOT MATCHED |
| 330012916 | 330003053 | null | 86.9 | Adjuvant (A) | 2013-04-15 | 2014-03-16 | Cisplatin + Radiotherapy | 02 | N | 330000542 | CISPLATIN + RT |
| 330012917 | 330003110 | null | null | Not known (9) | 2014-04-25 | 2014-04-25 | Cisplatin + Radiotherapy | 02 | null | 330000894 | CISPLATIN + RT |
| 330012918 | 330012744 | 1.76 | 69 | Curative (C) | null | 2014-12-24 | Cisplatin 100 + RT(H&N) 1 day | 2 | Y | 330001612 | CISPLATIN + RT |
| 330012919 | 330007725 | 1.06 | 12.1 | Curative (C) | 2017-11-07 | 2017-11-13 | NB HRNBL-1 BUMEL MAT | 02 | N | 330002044 | NOT MATCHED |
| 330012920 | 330003301 | 1.82 | 33.6 | Neo-adjuvant (N) | 2014-06-28 | 2014-06-29 | DAUNORUBICIN + PEGASPARAGINASE + VINCRISTINE | N | null | 330002460 | NOT MATCHED |
| 330012921 | 330003461 | 1.6 | 18.1 | Adjuvant (A) | 2015-05-22 | 2015-06-19 | NB HRNBL-1 COJEC Ind COURSE C | N | null | 330003386 | NOT MATCHED |
| 330012922 | 330003489 | null | 60.2 | Palliative (P) | 2015-08-22 | 2015-08-23 | Cisplatin 100 + RT(H&N) 1 day | null | Y | 330003518 | CISPLATIN + RT |
| 330012923 | 330003500 | 0 | 21 | Palliative (P) | 2017-09-01 | 2017-09-07 | NB HRNBL-1 COJEC Ind COURSE B | null | null | 330003568 | NOT MATCHED |
| 330012924 | 330003534 | null | 21.3 | Curative (C) | 2014-01-28 | 2015-01-05 | NB HRNBL-1 COJEC Ind COURSE C | 02 | N | 330003735 | NOT MATCHED |
| 330012925 | 330003537 | 1.76 | 54.9 | Curative (C) | 2017-09-02 | 2017-09-02 | CISPLATIN + RT | null | null | 330003743 | CISPLATIN + RT |
| 330012927 | 330007902 | 0 | 125.7 | null | 2015-12-10 | 2015-12-21 | NB HRNBL-1 COJEC Ind COURSE C | N | N | 330004842 | NOT MATCHED |
| 330012928 | 330003552 | 0.98 | null | null | 2017-09-08 | 2017-09-30 | CNS LGG 2004 03 cons vinc +cyclo | N | null | 330004963 | NOT MATCHED |
| 330012929 | 330003553 | null | 29.3 | Adjuvant (A) | 2015-12-24 | 2017-05-21 | NB HRNBL-1 COJEC Ind COURSE C | 2 | N | 330004971 | NOT MATCHED |
| 330012930 | 330003566 | 1.59 | 65.7 | Adjuvant (A) | 2014-07-19 | 2014-09-27 | Cisplatin + Radiotherapy | null | N | 330005102 | CISPLATIN + RT |
| 330012931 | 330003604 | 0 | 21.3 | Curative (C) | 2014-12-29 | 2014-12-30 | NB HRNBL-1 COJEC Ind COURSE A | N | N | 330005305 | NOT MATCHED |
| 330012932 | 330003611 | null | 16.2 | Adjuvant (A) | 2015-10-01 | 2015-12-02 | CISPLATIN + DACTINOMYCIN + ETOPOSIDE + FILGRASTIM + METHOTREXATE | Y | null | 330005334 | NOT MATCHED |
| 330012933 | 330003618 | 0 | 14.2 | Palliative (P) | 2016-07-10 | 2016-07-17 | NB HRNBL-1 Isotretinoin | N | N | 330005388 | NOT MATCHED |
| 330012934 | 330003627 | 1.55 | 75 | Curative (C) | 2016-07-24 | 2016-11-02 | Doxorubicin 75mg/m2 | Y | N | 330005461 | DOXORUBICIN |